Technical Analysis for GHDX - Genomic Health, Inc.

Grade Last Price % Change Price Change
grade B 72.7 3.05% 2.15
GHDX closed up 3.05 percent on Friday, January 18, 2019, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical GHDX trend table...

Date Alert Name Type % Chg
Jan 18 Crossed Above 50 DMA Bullish 0.00%
Jan 18 Pocket Pivot Bullish Swing Setup 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Up 3 Days in a Row Strength 0.00%
Jan 18 Up 4 Days in a Row Strength 0.00%
Jan 17 50 DMA Resistance Bearish 3.05%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.05%
Jan 17 Multiple of Ten Bullish Other 3.05%
Jan 17 Overbought Stochastic Strength 3.05%
Jan 17 Up 3 Days in a Row Strength 3.05%

Older signals for GHDX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company provides the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. It also offers the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer. Genomic Health, Inc. was founded in 2000 and is headquartered in Redwood City, California.
Is GHDX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 92.18
52 Week Low 30.04
Average Volume 462,840
200-Day Moving Average 57.1724
50-Day Moving Average 71.3186
20-Day Moving Average 66.119
10-Day Moving Average 69.681
Average True Range 3.1743
ADX 15.2
+DI 23.3208
-DI 15.207
Chandelier Exit (Long, 3 ATRs ) 64.1171
Chandelier Exit (Short, 3 ATRs ) 67.9979
Upper Bollinger Band 74.0569
Lower Bollinger Band 58.1811
Percent B (%b) 0.91
BandWidth 24.01095
MACD Line 0.5679
MACD Signal Line -0.4083
MACD Histogram 0.9763
Fundamentals Value
Market Cap 2.51 Billion
Num Shares 34.5 Million
EPS -0.15
Price-to-Earnings (P/E) Ratio -484.67
Price-to-Sales 3.41
Price-to-Book 6.72
PEG Ratio -149.73
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 77.85
Resistance 3 (R3) 77.59 75.61 76.99
Resistance 2 (R2) 75.61 74.30 75.74 76.70
Resistance 1 (R1) 74.16 73.49 74.89 74.42 76.42
Pivot Point 72.18 72.18 72.55 72.31 72.18
Support 1 (S1) 70.73 70.87 71.46 70.99 68.98
Support 2 (S2) 68.75 70.06 68.88 68.70
Support 3 (S3) 67.30 68.75 68.41
Support 4 (S4) 67.56